GMT Capital’s vTv Therapeutics VTVT Stock Holding History

GMT Capital’s Portfolio VTVT Stock Details VTVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-23,478	Closed	-$3.82M	–	115
2018 Q1	$3.82M	Buy	+23,478	New	+$5.75M	0.09%	83

Other funds holding VTVT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return

GMT Capital's VTVT Position: Q2 2018 in Review

GMT Capital sold out of vTv Therapeutics (VTVT) in Q2 2018, closing a stake of 23,478 shares — an estimated $3.82M sold.

GMT Capital first reported a position in VTVT in Q1 2018 and held it in 1 quarter. The position peaked at $3.82M in Q1 2018. 27 funds tracked by Wall St. Rank hold VTVT as of Q2 2018.

GMT Capital reported no remaining vTv Therapeutics position as of Q2 2018 after selling out during the quarter.
GMT Capital sold 23,478 vTv Therapeutics shares in Q2 2018, an estimated $3.82M.
GMT Capital first reported a position in vTv Therapeutics in Q1 2018 and held it in 1 quarter.
GMT Capital's vTv Therapeutics position peaked at $3.82M in Q1 2018.
27 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2018.

Based on GMT Capital's 13F filing for Q2 2018, filed 14 Aug 2018.